Empagliflozin in the treatment of type 2 diabetes: evidence to date
نویسندگان
چکیده
منابع مشابه
Empagliflozin in the treatment of type 2 diabetes: evidence to date
In the last decade, researchers have gained a greater understanding of the pathophysiologic mechanisms of type 2 diabetes as a chronic and progressive disease. One of the more recent treatment targets is the kidney. The kidneys become maladaptive in diabetes by increasing the reabsorption of glucose above the normal physiologic renal threshold. This discovery has led to the development of the s...
متن کاملSpotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides grea...
متن کاملPharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملThe effect of family-centered care on adherence to treatment in patients with type 2 diabetes
Background: Due to the prevalence of mortality due to complications of diabetes, this disease has focused on the health system.The family as the most basic pillar of society is responsible for the proper care of the patient with diabetes. Therefore, this study aimed to determine the effect of family-based care on adherence to treatment in type 2 diabetic patients. Materials & Methods: In quasi...
متن کاملEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
BACKGROUND The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Design, Development and Therapy
سال: 2015
ISSN: 1177-8881
DOI: 10.2147/dddt.s69926